Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,064 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Group 1: Placebo Clear all

Conditions: Sturge Weber Syndrome, Port-wine Mark
Interventions: Timolol, Preservative free artificial tear gel.; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 2 Years to 10 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetic Macular Edema
Interventions: Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402, Placebo: Group 4 - Placebo; Drug · Other
Lead sponsor: Rezolute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more

Conditions: Pain, Postoperative
Interventions: IV Acetaminophen, PO Acetaminophen, PO Placebo, IV Solution Placebo; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chikungunya Virus
Interventions: CHIKV VLP/adjuvant, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 12 Years to 64 Years
Enrollment: 3,258 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 47
States / cities: Huntsville, Alabama • Mobile, Alabama • Tempe, Arizona + 42 more

Conditions: Schizophrenia Disorders
Interventions: Placebo (single and multiple doses), AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Glendale, California • Willingboro, New Jersey

Conditions: Major Depressive Disorder
Interventions: Agomelatine (AGO178C), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 47
States / cities: Birmingham, Alabama • Beverly Hills, California • Encino, California + 41 more

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 7
States / cities: Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more

Conditions: Gonorrhoea
Interventions: Meningococcal Group B Vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Pain
Interventions: Baclofen 10mg, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Alcoholism
Interventions: Placebo Oral Tablet, Naltrexone; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 64 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Spasticity
Interventions: Corabotase, Placebo, Dysport; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 5
States / cities: Downey, California • Overland Park, Kansas • Farmington Hills, Michigan + 2 more

Conditions: Pain Management, Abortion, Second Trimester Abortion, Dilation and Evacuation
Interventions: Ketorolac, oral ibuprofen, Placebo, Lidocaine HCl 1%, Saline; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions: EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Resilience, HIV-1-infection, Stress, Psychological
Interventions: RISE+, Stress Reduction Control; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 50 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cocaine Use Disorder
Interventions: STP7 (mavoglurant), Placebo, Cocaine Hydrochloride; Drug
Lead sponsor: Stalicla SA; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Adolescent Idiopathic Scoliosis
Interventions: Caffeine Tablet, Placebo; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 12 Years to 17 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Arthritis, Rheumatoid
Interventions: Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri

Conditions: Oxidative Stress, Muscle Strength, Resistance Training, Body Composition, Muscle Damage
Interventions: Cross Training Course, Oceanix; Other · Dietary Supplement
Lead sponsor: Applied Science & Performance Institute; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Refractory Partial Seizures
Interventions: E2007 (perampanel), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more

Conditions: Schizophrenia
Interventions: SEP-363856, Placebo - Cap; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Little Rock, Arkansas • Garden Grove, California • Pico Rivera, California + 3 more

Conditions: Phantom Limb Pain, Phantom Pain, Phantom Sensation, Pseudomelia
Interventions: Sham (Comparator) Plasma Ball, Mirror; Device
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years to 30 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hidradenitis Suppurativa
Interventions: Sonelokimab (M1095), Adalimumab, Placebo; Drug · Other
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 15
States / cities: Fountain Valley, California • Los Angeles, California • Miami, Florida + 12 more

Conditions: Healthy
Interventions: VGX-1027; Drug
Lead sponsor: VGX Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lewy Body Dementia, Parkinson Disease
Interventions: Sitagliptin, Dapagliflozin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 45 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)

Preoperative IV Versus Oral Acetaminophen

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

Baclofen as a Perioperative Analgesic Adjuvant

Understanding Treatment Response With Naltrexone Among White Alcoholics

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

Paracervical Block With Combined Ketorolac and Lidocaine for Osmotic Dilator Placement

Topical Insulin for Glaucoma (TING2)

Testing the Efficacy and Mechanisms of an Adapted Resilience Building Intervention in People Aging With HIV

Phase1, STP7 Cocaine Drug-Drug Interaction Study

Oral Caffeine Use for Pain Management in AIS Patients After Spinal Fusion

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

The Effects of Antioxidant Supplementation on Multiple Endurance Race Performance, Physiology, and Recovery.

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia

Perioperative Mirror Therapy and Phantom Limb Pain

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects

Anti-Diabetic Medications to Fight PD and LBD